SHINGRIX subst sèche c solv (susp) 10 x 0.5 ml

7680679870024 CH-67987 J07BK03 08.08.
SHINGRIX subst sèche c solv (susp) 10 x 0.5 ml
SHINGRIX subst sèche c solv (susp) 10 x 0.5 ml
SHINGRIX subst sèche c solv (susp) 10 x 0.5 ml
1 / 3
google

Details

Product number
6798701
CPT
-
Packaging group
10 + 10
Unit
Durchstechflasche(n)
Composition
Pulver: glycoproteini E viri Varicellae Zoster antigenum 50 µg, saccharum, polysorbatum 80, natrii dihydrogenophosphas dihydricus, dikalii phosphas anhydricus, pro praeparatione. Solvens: adeps A 3-O-desacyl-4’-monophosphorylatus, Quillajae saponariae Molina saponinum purificatum, 1,2-dioleoyl-sn-glycero-3-phosphocholinum, cholesterolum, dinatrii phosphas, kalii dihydrogenophosphas, natrii chloridum, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml. Suspensio reconstituta: glycoproteini E viri Varicellae Zoster antigenum 50 µg, saccharum, polysorbatum 80, adeps A 3-O-desacyl-4’-monophosphorylatus, Quillajae saponariae Molina saponinum purificatum, 1,2-dioleoyl-sn-glycero-3-phosphocholinum, cholesterolum, natrii chloridum, natrii dihydrogenophosphas anhydricus, dikalii phosphas anhydricus, dinatrii phosphas, kalii dihydrogenophosphas, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 1.77 mg, kalium 0.18 mg.

Articles (1)

Shingrix, Pulver und Suspension zur Herstellung einer Injektionssuspension
Pulver
10 + 10
View

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Professional SmPC
Allemand
11/07/2026
Professional SmPC
Français
11/07/2026
Professional SmPC
Italien
11/07/2026

Detailed composition

Substance Quantity Type Category
glycoproteini E viri Varicellae Zoster antigenum
50.0 UG Substance Wirkstoff (Principe actif)
adeps A 3-O-desacyl-4’-monophosphorylatus
- Substance HNIDK
glycoproteini E viri Varicellae Zoster antigenum
50.0 UG Substance Wirkstoff (Principe actif)
Quillajae saponariae Molina saponinum purificatum
- Substance HNIDK
saccharum
- Substance HNIDK
saccharum
- Substance HNIDK
polysorbatum 80
- Substance HNIDK
polysorbatum 80
- Substance HNIDK
1,2-dioleoyl-sn-glycero-3-phosphocholinum
- Substance HNIDK
cholesterolum
- Substance HNIDK
adeps A 3-O-desacyl-4’-monophosphorylatus
- Substance HNIDK
natrii dihydrogenophosphas dihydricus
- Substance HNIDK
dikalii phosphas anhydricus
- Substance HNIDK
dinatrii phosphas
- Substance HNIDK
Quillajae saponariae Molina saponinum purificatum
- Substance HNIDK
kalii dihydrogenophosphas
- Substance HNIDK
1,2-dioleoyl-sn-glycero-3-phosphocholinum
- Substance HNIDK
natrii chloridum
- Substance HNIDK
cholesterolum
- Substance HNIDK
natrii chloridum
- Substance HNIDK
aqua ad iniectabile
- Substance HNIDK
natrii dihydrogenophosphas anhydricus
- Substance HNIDK
dikalii phosphas anhydricus
- Substance HNIDK
dinatrii phosphas
- Substance HNIDK
kalii dihydrogenophosphas
- Substance HNIDK
aqua ad iniectabile
- Substance HNIDK
natrium
1.77 MG Substance HBESI
kalium
0.18 MG Substance HBESI

Authorization holder

GlaxoSmithKline AG

6340 Baar

Authorization information

Swissmedic authorization number
67987
Drug name
Shingrix, Pulver und Suspension zur Herstellung einer Injektionssuspension
Galenic form
PULVS
ATC Code
J07BK03
Authorization status
Z
Dispensation category
B
First authorization
07/10/2021
Authorization expiration date
31/12/9999
IT number
08.08.
Domain
Human medicine
Field of application
Prävention von Herpes Zoster

Packaging details

Description (FR)
SHINGRIX subst sèche c solv (susp) 10 x 0.5 ml
Description (DE)
SHINGRIX Trockensub c Solv (Susp) 10 x 0.5 ml
Market launch
07/10/2021
Narcotic (BTM)
No

Other packaging sizes

SHINGRIX subst sèche c solv (susp) flac 0.5 ml
1 + 1 DUR
View
Buy us a coffee Explore the data